Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment

Recruiting now

Conditions studied: Cervical Cancer

In brief

The purpose of this study is to determine if ctHPVDNA (circulating tumor HPV DNA) can be used as a non-invasive biomarker for identification and treatment monitoring of cervical cancer by characterizing correlation between plasma ctHPVDNA, urine transrenal HPVDNA (TrHPVDNA) levels and presence of cervical cancer at diagnosis and following definitive intent management.

Key facts

Study ID

NCT04743674

Run by

UNC Lineberger Comprehensive Cancer Center

People needed

30

Starts

2024-05-03

Expected to finish

2027-01-15

Last updated by the study team

2026-05-12

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older on day of signing informed consent
• New diagnosis of cervical cancer
• Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee

You may not qualify if…

• Women who are pregnant

Where it is running

• Melissa Knutsen — Chapel Hill, North Carolina, United States (enrolling)
• Kamuzu Central Hospital — Lilongwe, Malawi

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.